We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
ARTICLE · 05 AUGUST 2014
A Compound Is Obvious Where Only Minor Changes To A Prior Art "Lead Compound" Are Required To Make The Claimed Compound
McDermott Will & Emery
Bristol-Myers (BMS) sued Teva for infringing a patent directed to entecavir, a nucleoside analogue with antiviral properties.
United StatesIntellectual Property







